×
App Icon
The Standard e-Paper
Fearless, Trusted News
★★★★ - on Play Store
Download App

US approves Gilead's twice-yearly injection to prevent HIV

Despite the impressive results, optimism may be tempered by the drug's cost. [AFP]

Drugs to prevent HIV transmission, known as pre-exposure prophylaxis or PrEP, have existed for more than a decade. But because they typically require taking a daily pill, they have yet to make a significant dent in global infections.

"This is a historic day in the decades-long fight against HIV," Gilead chairman and chief executive Daniel O'Day said in a statement.

Premium Article

Get Full Access for Ksh299/Week.

Uncover the stories others won't tell. Subscribe now for exclusive access.
Continue Reading  →
What you get
  • Unlimited access to all premium content
  • Ad-free browsing experience
  • Mobile-optimised reading
  • Weekly newsletters & digests
Pay via
M - PESA
VISA
Airtel Money
Secure Payments Kenya's most trusted newsroom since 1902
Support Independent Journalism

Stand With Bold Journalism.
Stand With The Standard.

Journalism can't be free because the truth demands investment. At The Standard, we invest time, courage and skills to bring you accurate, factual and impactful stories. Subscribe today and stand with us in the pursuit of credible journalism.

Pay via
M - PESA
VISA
Airtel Money
Secure Payment Kenya's most trusted newsroom since 1902